Curcumin and liver toxicity

You've probably seen the chatter on social media lately - influencers and health advocates are talking about curcumin supplements causing liver problems. If you're wondering what this means for your health journey (and your HOP Box), we've got you covered with the facts you need to make informed decisions.

What's happening with curcumin?

Recent reports have highlighted a concerning trend: liver toxicity cases linked to curcumin supplements have been increasing. The Drug-Induced Liver Injury Network documented ten confirmed cases between 2011 and 2022, with most occurring since 2017. Five patients required hospitalization, and tragically, one person died from acute liver failure.

These aren't just minor side effects – we're talking about liver enzyme levels spiking 60-70 times above normal, similar to what you'd see with viral hepatitis.

Why is this happening?

The liver toxicity issue comes down to three main factors:

1. Dose matters. Many commercial curcumin supplements contain 2,000-3,000 mg per daily dose – that's 10-15 times higher than the World Health Organization's recommended safe daily intake of 210 mg for a 70 kg adult.
   
   
2. The piperine problem. Some curcumin supplements include piperine (black pepper extract) to boost absorption by up to 2,000%. While this sounds good in theory, it can transform curcumin from a poorly absorbed compound into one that reaches potentially toxic levels in your system.
   
   
3. Genetic susceptibility. Research shows that 70% of people who developed curcumin-induced liver injury carry a specific genetic variant (HLA-B*35:01) that makes them particularly vulnerable. This affects only about 6% of the general population, but for those people, even standard doses can be dangerous.

The supplement combination trap

Curcumin becomes even riskier when combined with certain medications or other supplements, including:

• Blood thinners like warfarin
• Diabetes medications
• Other liver-processed supplements like green tea extract or kava
• Chemotherapy drugs

Enter tetrahydrocurcumin (THC): curcumin's safer cousin

Here's where the HOP story gets exciting. When we were formulating our Damage Control blend, we knew we wanted the benefits of curcuminoids without the risks. That's why we chose CurcuPrime® tetrahydrocurcumin (THC) instead of regular curcumin.

What makes THC different?

Tetrahydrocurcumin is curcumin's primary metabolite – essentially what curcumin becomes in your body after it's processed. But here's the game-changer: THC lacks the specific chemical structures that contribute to curcumin's liver toxicity risk.

The safety profile speaks for itself

• Extensive 90-day safety studies showed no adverse effects at doses up to 400 mg/kg/day in animals
• The European Food Safety Authority approved THC as safe for adults
• Zero reported cases of liver toxicity with THC supplementation
• Animal studies actually show THC may be liver-protective

Better bioavailability, naturally

Unlike curcumin, THC achieves higher absorption without needing piperine or other enhancers, eliminating the primary risk factor while maintaining all the anti-inflammatory and antioxidant benefits you're looking for.

Curcumin vs. tetrahydrocurcumin: comprehensive comparison

What this means for your HOP journey

Every HOP Box contains 200 mg of CurcuPrime® tetrahydrocurcumin in our Damage Control blend – a dose that's both safe and effective. We chose this ingredient specifically because we believe in providing you with the most scientifically sound, safest options available.

This is why education and community matter so much in the longevity space. The supplement industry is full of "more is better" marketing, but smart supplementation is about precision, not just power.

Your action items

If you're currently taking curcumin supplements outside of HOP Box:

• Check the dose and avoid anything over 200 mg daily. 
• Look for piperine on the label and consider alternatives. 
• If you're taking blood thinners, diabetes medication, or other liver-processed supplements, talk to your healthcare provider. 
• Watch for warning signs: nausea, fatigue, dark urine, or yellowing of skin/eyes.

The bigger picture

This curcumin situation perfectly illustrates why we're so passionate about education in the longevity space. "Natural" doesn't automatically mean safe, and more isn't always better. At HOP, we're committed to cutting through the noise and providing you with science-backed solutions that support your journey without unnecessary risks.

HOP to it! 

References 

1. Sohal, A., Alhankawi, D., Sandhu, S., & Chintanaboina, J. (2021). Turmeric-induced hepatotoxicity: Report of 2 cases. Case Reports in Gastroenterology, 15(3), 799-805. https://pmc.ncbi.nlm.nih.gov/articles/PMC8711139/
   
   
2. Halegoua-DeMarzio, D., Navarro, V., Ahmad, J., Avula, B., Barnhart, H., Bonkovsky, H. L., ... & Vuppalanchi, R. (2023). Liver injury associated with turmeric—a growing problem: Ten cases from the drug-induced liver injury network. The American Journal of Medicine, 136(2), 200-206. https://www.sciencedirect.com/science/article/abs/pii/S0002934322007409
   
   
3. Papke Jr, D. J., Viveiros, K., Zota, V., Gill, R. M., González, I. A., Misdraji, J., & Patil, D. T. (2025). Turmeric supplement-associated hepatitis: A clinicopathological series of 11 cases highlighting pan-lobular and zone 3 injury. Histopathology, 86(3), 410-422. https://pubmed.ncbi.nlm.nih.gov/39381846/
   
   
4. Patel, S., Sharma, V., Chauhan, N. S., & Thakur, M. (2021). An open label, single arm, prospective clinical study to evaluate liver safety and tolerability of PUREMERIC™ (standardized extract from Curcuma longa) in healthy subjects. Toxicology Reports, 8, 1955-1959. https://pmc.ncbi.nlm.nih.gov/articles/PMC8646164/
   
   
5. Navarro, V. J., Sharma, A., Navarro, V. J., Bonkovsky, H. L., Vuppalanchi, R., Avula, B., ... & Hoofnagle, J. H. (2021). HLA-B*35:01 and green tea–induced liver injury. Hepatology, 73(6), 2484-2493. https://pmc.ncbi.nlm.nih.gov/articles/PMC8052949/
   
   
6. Danan, G., Jain, A., Avula, B., Barnhart, H., Bonkovsky, H. L., Fontana, R. J., ... & Vuppalanchi, R. (2025). Drug-induced liver injury associated with turmeric and piperine. Case Reports in Gastroenterology, 19(1), 140-148. https://pmc.ncbi.nlm.nih.gov/articles/PMC11850025/
   
   
7. Karger, J. M., Smith, P. R., & Johnson, L. K. (2025). A case of turmeric-induced hepatotoxicity with hyperferritinemia. Case Reports in Gastroenterology, 19(1), 140-148. https://karger.com/crg/article/19/1/140/922677/A-Case-of-Turmeric-Induced-Hepatotoxicity-with
   
   
8. Kotecha, R., Takami, A., & Espinoza, J. L. (2018). Subchronic and reproductive/developmental toxicity studies of tetrahydrocurcumin in rats. Food and Chemical Toxicology, 115, 324-334. https://pmc.ncbi.nlm.nih.gov/articles/PMC6354947/
   
   
9. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). (2021). Safety of tetrahydrocurcuminoids from turmeric (Curcuma longa L.) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal, 19(12), e06936. https://www.efsa.europa.eu/en/efsajournal/pub/6936
   
   
10. Pari, L., & Murugan, P. (2004). Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity. Pharmacological Research, 49(5), 481-486. https://pubmed.ncbi.nlm.nih.gov/14998559/
    
    
11. Luo, D. D., Chen, J. F., Liu, J. J., Xie, J. H., Zhang, Z. B., Gu, J. Y., ... & Sun, Z. H. (2019). Tetrahydrocurcumin and octahydrocurcumin, the primary and final hydrogenated metabolites of curcumin, possess superior hepatic-protective effect against acetaminophen-induced liver injury. Food and Chemical Toxicology, 123, 349-362. https://pubmed.ncbi.nlm.nih.gov/30423402/
    
    
12. Deshpande, S. S., Ingle, A. D., & Maru, G. B. (1998). Subchronic oral toxicity of turmeric and ethanolic turmeric extract in female Swiss mice and Wistar rats. Food and Chemical Toxicology, 36(11), 987-995. https://cot.food.gov.uk/Turmeric_Curcumin_Second_draft_statement
    
    
13. Fang, Z., Zhao, J., Shi, G., Shu, Y., Wang, L., Zhao, H., & Zhang, J. (2016). Overdose intake of curcumin initiates the unbalanced state of bodies. Journal of Agricultural and Food Chemistry, 64(13), 2765-2771. https://pubs.acs.org/doi/abs/10.1021/acs.jafc.6b00053
    
    
14. Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M., Ho, Y. F., Shen, T. S., ... & Hsieh, C. Y. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Research, 21(4B), 2895-2900. https://pubmed.ncbi.nlm.nih.gov/11712783/
    
    
15. Shehzad, A., Qureshi, M., Anwar, M. N., & Lee, Y. S. (2018). Curcumin in various cancers. BioFactors, 39(1), 56-68. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00554/full
    
    
16. Majeed, M., Nagabhushanam, K., Natarajan, S., & Vaidyanathan, P. (2021). The enhanced bioavailability of free curcumin and bioactive tetrahydrocurcumin: A randomized, double-blind, crossover study. Medicine, 100(27), e26713. https://pubmed.ncbi.nlm.nih.gov/34232211/
    
    
17. Abdel-Daim, M. M., Ghazy, E. W., Abdel-Daim, M. H., Eltaysh, R., & Kumar, A. (2021). Evaluation of the hepatoprotective effects of curcumin and nanocurcumin against paraquat-induced liver injury in rats. British Journal of Pharmacology, 178(3), 646-661. https://europepmc.org/article/med/33544450
    
    
18. Rahimi, H. R., Mohammadpour, A. H., Dastani, M., Jaafari, M. R., Abnous, K., Mobarhan, M. G., & Oskuee, R. K. (2016). The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects. Phytotherapy Research, 30(7), 1052-1058. https://europepmc.org/article/pmc/6132848
    
    
19. Pari, L., & Murugan, P. (2007). Influence of tetrahydrocurcumin on hepatic and renal functional markers and protein levels in experimental type 2 diabetic rats. Basic & Clinical Pharmacology & Toxicology, 101(2), 109-115. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1742-7843.2007.00109.x
    
    
20. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics, 4(6), 807-818. https://pmc.ncbi.nlm.nih.gov/articles/PMC3535097/